What is Neurotrack?
Neurotrack operates at the intersection of neurology and digital health, providing a scalable platform for the assessment, monitoring, and strengthening of brain health. By enabling remote cognitive testing from the privacy of a patient's home, the company effectively lowers the barrier to entry for early detection of cognitive decline. This digital-first approach is critical for clinical research and long-term patient management, positioning Neurotrack as a vital infrastructure player in the fight against neurodegenerative diseases.
The company's market position is bolstered by its ability to integrate seamlessly into existing healthcare workflows, providing clinicians with actionable data that was previously difficult to capture outside of specialized clinical settings. By leveraging advanced data analytics, Neurotrack transforms subjective cognitive health metrics into objective, longitudinal insights.
How much funding has Neurotrack raised?
Neurotrack has raised a total of $47.6M across 5 funding rounds:
Series A
$2M
Debt
$1M
Private Equity
$9.9M
Series B
$13.7M
Series C
$21M
Series A (2013): $2M with participation from The Social+Capital Partnership and Founders Fund
Debt (2014): $1M, investors not publicly disclosed
Private Equity (2015): $9.9M supported by AME Cloud Ventures, Khosla Ventures, Founders Fund, iSeed Ventures, and Social Capital
Series B (2018): $13.7M featuring Rethink Impact, Social Capital, Sozo Ventures, Marc Benioff, Khosla Ventures, AME Cloud, and Founders Fund
Series C (2019): $21M backed by Khosla Ventures, AME Cloud Partners, Dai-ichi Life, SOMPO Holdings, Rethink Impact, and Sozo Ventures
Key Investors in Neurotrack
Khosla Ventures
A prominent venture firm founded by Vinod Khosla, specializing in breakthrough technologies across sectors including health, AI, and enterprise software.
Founders Fund
A high-conviction venture capital firm known for backing transformative companies and providing founder-friendly support across all stages of growth.
Rethink Impact
A venture capital firm focused on investing in technology platforms that drive measurable social impact, with a strong emphasis on healthcare and mental health.
What's next for Neurotrack?
With the capital secured in its latest major strategic investment, Neurotrack is well-positioned to accelerate its commercial expansion and deepen its clinical validation efforts. The company is expected to focus on scaling its enterprise partnerships, particularly with large-scale healthcare providers and insurance entities that are increasingly prioritizing preventative cognitive care. Furthermore, the firm will likely continue to refine its digital platform, incorporating more sophisticated AI-driven diagnostics to enhance the accuracy and predictive power of its cognitive health assessments.
As the global population ages, the demand for accessible, remote-first neurological monitoring is projected to surge. Neurotrack's strategic roadmap suggests a continued emphasis on global market penetration and the development of new therapeutic interventions, ensuring the company remains at the forefront of the digital health revolution.
